Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection. He commented: “The people who run this company are not idiots. They’ve long known that Keytruda would lose patent protection, so, for years, they’ve been making acquisitions to build up their pipeline… Verona is focused on respiratory diseases, and they already have one drug on the market, the first new main ...